secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-104546
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx Q2 net loss narrows to $41.4M; cash $180.8M; pipeline milestones on track
--------------------------------------------------------------------------------

- Net loss of $41.4M ($0.46 per share) vs $72.7M ($1.07) in Q2 2024; lower SG&A and R&D spend in ALS.
- Cash, equivalents, and marketable securities $180.8M at June 30, 2025; runway expected through end of 2026.
- Pivotal Phase 3 LUCIDITY trial of avexitide in PBH fully enrolled in 2025; topline data H1 2026; potential launch 2027.
- Phase 2b ORION trial (AMX0035) in PSP unblinded analysis expected Q3 2025 to inform Phase 3 go/no-go.
- FDA Fast Track granted for AMX0114 (antisense oligo) in ALS; early LUMINA Phase 1 data expected 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000095017025104546/0000950170-25-104546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000095017025104546/amlx-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer